Company Files Fiscal Form 10-Q's for First Three Quarters of Fiscal 2008
and Form 10-K for Fiscal 2008 Ended March 31, 2008
Points to Positive Fiscal 2009 Outlook for Its Branded and Generic
ST. LOUIS, June 25 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and generic/non-branded prescription pharmaceutical products, today announced that it has filed Form 10-Q's for the quarters ended June 30, 2007, September 30, 2007 and December 31, 2007, as well as a Form 10-K for its 2008 fiscal year ended March 31, 2008. The financial data included in these filings is consistent with previously reported preliminary financial results.
Marc S. Hermelin, Chairman of the Board and Chief Executive Officer stated, "With the filing of our fiscal 2008 financial reports, the Company is now up to date with its Securities and Exchange Commission filings. Fiscal 2008 was an extraordinary year for KV filled with many accomplishments by both our branded and generic businesses. Our Company continued to perform at record levels despite a difficult industry environment. We fully expect to continue our strong performance in fiscal 2009 and beyond as we execute on our branded and generic strategies and seek to capitalize on our valuable product pipeline."
Mr. Hermelin continued, "As previously reported, KV generated net
revenue and net income increases of 36% and 52%, respectively, for fiscal
2008 compared to the prior year. In fiscal 2009 the Company expects to
introduce 8-10 new products from Ther-Rx and ETHEX combined, which includes
the anticipated approval of six ANDA's and one NDA. The anticipated new
products, continued momentum from KV's generic Metoprolol Succinate
Extended Release tablets, and expansion of the Company's branded women
|SOURCE KV Pharmaceutical Company|
Copyright©2008 PR Newswire.
All rights reserved